Delta-type opioid receptor (OPRD1) Antibody

Background

OPRD1, also known as the delta-opioid receptor, is a G protein-coupled receptor (GPCR) activated by endogenous opioid peptides such as enkephalins. It is expressed in the central nervous system (CNS), including the cortex, limbic system, and spinal cord, where it modulates pain perception, mood regulation, and neuroprotection. OPRD1 couples to Gi/o proteins, inhibiting adenylate cyclase activity, reducing cAMP levels, and modulating ion channel activity to decrease neuronal excitability. Activation of OPRD1 produces analgesic effects, particularly in chronic and neuropathic pain conditions. It is also involved in regulating mood and emotional behaviors, with potential roles in reducing anxiety and depressive symptoms. Dysregulation of OPRD1 has been linked to pain disorders, addiction, and mood dysregulation. Selective OPRD1 agonists are being explored for their analgesic properties with lower addiction potential compared to mu-opioid receptor agonists. OPRD1 modulation represents a promising therapeutic approach for pain management, mood disorders, and neuroprotection.